hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 22:38:08 - browse：97

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： States should stop sabotaging methadone treatment reform

leisure time

WSS

Merck drug for rare lung condition set for approval in U.S.

Wegovy leads to weight loss. Can it treat depression, too?

Supreme Court mifepristone arguments center on docs' right to sue

Syphilis numbers in the United States reach record heights

Roche subsidiary Foundation Medicine opens new headquarters

Merck drug for rare lung condition set for approval in U.S.

entertainment

hotspot

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Philips to halt sales of sleep apnea machines in U.S.

Medical records are filled with copy

FDA's naming rule on biosimilars has undermined competition

Cancer drug shortages should be causing more outrage

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The high cost of giving birth even with insurance

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Cancer drug shortages should be causing more outrage

Investment in vaccine development is lagging, report finds

focus

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Vertex non

Biogen walks away from Aduhelm, years after polarizing approval

Supreme Court mifepristone arguments center on docs' right to sue

Abortion pill case raises question: who can sue the FDA?

Merck CEO won’t testify in Senate, citing no expertise in drug prices

hotspot

leisure time

hotspot

hotspot